Iota Biosciences Founder to Keynote 2026 Bioelectronic Medicine Forum in NYC

The selection of Jose Carmena, co-founder of Iota Biosciences, as the keynote speaker for the 2026 Bioelectronic Medicine Forum marks a significant milestone for the "electroceuticals" industry. As the field moves from experimental research into late-stage clinical applications, the focus has shifted toward the miniaturization and power-efficiency of neural interfaces. Iota Biosciences, which was acquired by Astellas Pharma in 2020 in a deal valued at approximately $304 million plus milestones, represents the vanguard of this transition. Their proprietary "neural dust" technology—millimeter-sized sensors powered by ultrasound—addresses one of the primary hurdles in bioelectronic medicine: the need for long-term, battery-free implantation.

At the heart of Iota’s technology is the "neural dust" concept, which uses ultrasound for both power and communication. This approach solves a fundamental engineering challenge in bioelectronic medicine: the "battery problem." Traditional implants from companies like Medtronic or Boston Scientific often require bulky batteries and invasive leads that can degrade over time or cause tissue damage. By utilizing ultrasound, Iota’s devices can be implanted deep within the body to monitor and stimulate specific nerves without the need for wires or frequent surgical replacements. This technology is particularly suited for targeting the peripheral nervous system to treat conditions like rheumatoid arthritis, Crohn’s disease, and even diabetes by modulating organ function directly through the vagus nerve and other neural pathways.

“

Iota Biosciences, which was acquired by Astellas Pharma in 2020 in a deal valued at approximately $304 million plus milestones, represents the vanguard of this transition.

The acquisition of Iota Biosciences by Astellas Pharma in 2020 served as a major validation of the bioelectronic medicine market. For a traditional pharmaceutical giant like Astellas, the move represented a strategic pivot toward "Rx+"—therapies that combine drugs with digital and physical technologies. This trend is accelerating across the industry as Big Pharma seeks to diversify its portfolios and find alternatives to systemic drugs that often carry significant side-effect profiles. The 2026 Forum will likely serve as a platform for Astellas to showcase the clinical progress made since the acquisition and to outline the regulatory roadmap for these Class III medical devices. The event in New York City is expected to draw a significant number of venture capitalists and pharmaceutical executives who are increasingly looking at bioelectronics as a viable alternative to biologics.

The bioelectronic medicine landscape is currently defined by a race toward "closed-loop" systems. These are devices that not only deliver therapeutic stimulation but also sense physiological biomarkers in real-time, allowing the system to adjust its output autonomously. Carmena’s keynote is expected to address the integration of artificial intelligence and machine learning into these interfaces. As these devices become smaller and more data-rich, the challenge shifts from hardware engineering to data science and biocompatibility. The 2026 Forum will be a critical gathering for the industry to assess which platforms are closest to achieving large-scale commercial viability and how they will integrate into the existing healthcare infrastructure.